ducovest

BAYZF:OTO-Bayer A G Ord (USD)

COMMON STOCK | Drug Manufacturers—General | OTC Pink

Last Closing

USD 60.5

Change

-1.25 (-2.02)%

Market Cap

USD 91.96B

Volume

0.02M

Analyst Target

N/A
Analyst Rating

N/A

ducovest Verdict

Verdict

About

Bayer AG is engaged in the development, production and marketing of prescription Pharmaceutical. Its business segments are pharmaceutical, Consumer Health, Crop Science, Animal Health, and Covestro.

Company Website : http://www.bayer.com

Currency: USD

Country : USA

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2020-04-08 )

Largest Industry Peers for Drug Manufacturers—General

ETFs Containing BAYZF

N/A

Market Performance

  Market Performance vs. Industry/Classification (Drug Manufacturers—General) Market Performance vs. Exchange (OTC Pink)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -25.54% 20% F 48% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -25.54% 20% F 48% F
Trailing 12 Months  
Capital Gain -12.28% 37% F 66% D+
Dividend Return 4.06% 85% B 70% C-
Total Return -8.22% 34% F 68% D+
Trailing 5 Years  
Capital Gain 59.47% 90% A- 81% B-
Dividend Return 16.54% 95% A 72% C
Total Return 76.01% 86% B+ 81% B-
Average Annual (5 Year Horizon)  
Capital Gain 67.87% 100% F 82% B
Dividend Return 70.36% 97% N/A 82% B
Total Return 2.49% 70% C- 56% F
Risk Return Profile  
Volatility (Standard Deviation) 153.38% 6% D- 21% F
Risk Adjusted Return 45.87% 78% C+ 76% C+
Market Capitalization 91.96B 71% C- 99% N/A

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

Underpriced compared to book value

The stock is trading low compared to its peers on a price to book value basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.

High dividend returns

The stock has outperformed its sector peers on average annual dividend returns basis in the past 5 years (for a hold period of at least 12 months) and is in the top quartile. This can be a good buy, especially if it is outperforming on total return basis , for investors seeking high income yields.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

What to not like:
Highly leveraged

The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.

Poor return on assets

The company management has delivered below median return on assets in the most recent 4 quarters compared to its peers.

Poor capital utilization

The company management has delivered below median return on invested capital in the most recent 4 quarters compared to its peers.

Poor return on equity

The company management has delivered below median return on equity in the most recent 4 quarters compared to its peers.

Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector

Low Revenue Growth

This stock has shown below median revenue growth in the previous 5 years compared to its sector